Navigation Links
Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study
Date:7/22/2009

12 weeks.

Number of patients (planned and analyzed):

The planned sample size of evaluable patients was 70 per arm (140 in total). Two hundred nineteen patients were randomized and enrolled; 109 and 110 patients were randomized to placebo and QR-333 treatment group, respectively.

Diagnosis and main criteria for inclusion:

Patients between the ages of 18 and 70 with a diagnosis of diabetic neuropathy were enrolled in the study.

Duration of treatment:

Treatment commenced at randomization (Visit 2) and continued for 12 weeks; study duration for each patient was approximately 22 weeks.

Endpoints:

Efficacy:

The primary efficacy objective is to demonstrate that treatment with QR-333 improves pain relief, as demonstrated through the VAS pain scale.

The secondary efficacy objective is to demonstrate that treatment with QR-333 improves symptomatic diabetic neuropathy, as demonstrated through the Symptom Assessment Score, Quality of Life questionnaires, and sleep questionnaires.

Safety:

Safety variables included adverse events (AEs), findings from physical and examinations, vital signs, laboratory safety data, 12-lead electrocardiograms (ECGs), and nerve conduction velocity (NCV) assessments.

About The Quigley Corporation

The Quigley Corporation (NASDAQ: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R
'/>"/>

SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer
2. Dr. Richard Rosenbloom Resumes Services To The Quigley Corporations Pharma Subsidiary
3. Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
4. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
5. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
6. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
7. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
8. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
9. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
10. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
11. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... pain clinic as a testing ground, researchers at Johns ... by Toyota in Japan can substantially reduce patient wait ... residents. , In a report on the pilot study, ... the researchers adopted the so-called "Just-in-Time" training and inventory ... to stem waste and keep complicated operations from bottlenecking. ...
(Date:9/16/2014)... Va. (PRWEB) September 16, 2014 ... through predictive analytics and targeted clinical programs, today ... announced changes support the Company’s drive to improve ... and targeted clinical programs. On September 2, 2014, ... company, Millennium Health, announced that RxAnte founder and ...
(Date:9/16/2014)... Thompson HealthDay Reporter MONDAY, ... strong heart fitness can delay a man,s onset of age-related ... suggests. Blood pressure naturally increases as people grow older ... with strong cardio-fitness don,t start drifting toward high blood pressure ... usually experience the early signs of high blood pressure in ...
(Date:9/16/2014)... early-stage lung cancer who receive stereotactic body radiation ... 40 percent, according to research presented today at ... Annual Meeting. Such a positive survival rate is ... poor tumor control for patients with inoperable lung ... 0236, originally published in 2010 , and also ...
(Date:9/16/2014)... West Orange, NJ. September 16, 2014. Kessler Foundation ... of slowed processing speed in the executive deficits ... "Does slowed processing speed account for executive deficits ... structural neuroimaging," was published online ahead of print ... The authors are Victoria Leavitt, PhD, ...
Breaking Medicine News(10 mins):Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3
... ... in designing cutting-edge training facility for Kodak Dental Systems that features practice management ... ... August 4, 2009 -- Advanced Automation, a leader in comprehensive IT solutions and ...
... , ROSEMONT, Ill., Aug. 4 ... such anesthetic drugs as Diprivan (propofol) by the late Michael Jackson, ... agents. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO ... and Maxillofacial Surgeons (AAOMS) and its 8,500 fellows and members who ...
... , , , ... (Pink Sheets: NXCO), developer of next generation digital media protection ... , a website that provides authors in the self-help/motivational market ... their downloadable materials. AmnestyQuest.com is a partnership between Nexicon and ...
... MINNEAPOLIS, Aug. 4 Court ordered Class Notice in Curtis, et al., ... , court File No. 27-CV-01-18042 (action filed 11/28/01). , , ... at any time before November 30, 2004, this class action notice may affect ... the marketing, advertising and promotion of Marlboro Lights cigarettes is pending in Hennepin ...
... , AVENTURA, Fla., Aug. 4 ... of highly specialized, nationally recognized orthopedic surgeons who have agreed ... business model of Centers of Excellence with Global Convenience(TM) ... orthopedic procedures domestically and abroad. The team represents a total ...
... ... has introduced a new technology offering including their new Scoreboard application. ... at a glance screen showing key business indicators updated in real-time. ... or both. The Scoreboard will be available to clients that either ...
Cached Medicine News:Health News:New Kodak Training Facility Showcases the Latest in Dental Technology, Solutions from Advanced Automation: Networking Solutions, Dental Practice Management and Dental X-Ray Integration 2Health News:New Kodak Training Facility Showcases the Latest in Dental Technology, Solutions from Advanced Automation: Networking Solutions, Dental Practice Management and Dental X-Ray Integration 3Health News:American Association of Oral and Maxillofacial Surgeons Says Only Trained Dental and Medical Practitioners Should Administer and Monitor Anesthesia 2Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 2Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 3Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 4Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 5Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 3Health News:Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons 2Health News:Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons 3Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 3
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, ... Boston and their first West Coast location in ... Street in Boston , and will house product ... Southern California office will be located at ... the demands of customers nationwide.  Both new locations will be ...
(Date:9/16/2014)... Sept. 16, 2014  Formex, LLC ("Formex"), ... that Mr. Greg Weilersbacher joined Formex as Director ... Greg Weilersbacher has ... focused expertise in Quality Assurance, Facility Validation, ... Weilersbacher brings to Formex a diverse wealth ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... R.I., Aug. 16, 2011 Medicare Part D beneficiaries ... pay 100 percent of previously subsidized prescription costs, are ... are to switch to more affordable or generic medications, ... concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) The ...
... Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... Phase III clinical studies in patients with refractory chronic ... of the American Medical Association ( JAMA ). ... significant and sustained reductions in uric acid levels along ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: